388870 — Pharos IBio Co Balance Sheet
0.000.00%
- KR₩134bn
- KR₩116bn
Annual balance sheet for Pharos IBio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 23,812 | 15,079 | 25,487 | 15,668 | 25,993 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 67.4 | 225 | 280 | 265 | 72.2 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 24,422 | 15,715 | 26,170 | 16,254 | 26,398 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,700 | 2,541 | 3,218 | 2,817 | 2,382 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 27,486 | 18,721 | 29,690 | 19,628 | 29,868 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 78,088 | 951 | 1,213 | 973 | 1,392 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 78,670 | 1,056 | 1,341 | 1,015 | 15,943 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -51,184 | 17,665 | 28,349 | 18,614 | 13,926 |
| Total Liabilities & Shareholders' Equity | 27,486 | 18,721 | 29,690 | 19,628 | 29,868 |
| Total Common Shares Outstanding |